ClinicalTrials.gg
Not yet recruitingNCT05996601CPCLINTUpdated Aug 18, 2023

Evaluation of Improved Outcomes Among Ambulatory Diabetes and/or Hypertensive Patients - an Intervention Study (CPCLINT)

An interventional study of Educational intervention in Type 2 Diabetes Mellitus and Hypertension, sponsored by University of Ibadan. Not yet recruiting at 1 site in Nigeria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-18.

Sponsored by University of Ibadan · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this interventional study is to compare improved outcomes among diabetes and/or hypertensive patients sequel to educational intervention. The study aims to answer the following questions:

  • What are the patients' levels of health literacy, medication adherence, disease knowledge, attitude to disease, physical activity?
  • Does educational intervention by pharmacists improve health outcomes of patients with diabetes and/or hypertension?
  • Are there associations between patient-related variables such as health literacy, medication adherence, disease knowledge, attitude to disease? Participants' anthropometric measurements and point-of-care testing for disease monitoring e.g., blood pressure, blood glucose would be carried out. Baseline assessment of participants would be done to evaluate their levels of health literacy, medication adherence, disease knowledge, attitude to disease, physical activity.

Patients' baseline assessment would be carried out, after which they would receive educational materials and would be followed up by pharmacist. The baseline assessments would be repeated at three and six months after the intervention to measure the effectiveness of the intervention.

Read the detailed description

The anthropometric measurements would include weight, height, waist circumference, hip circumference, from which the body mass index and waist-hip ration would be calculated.

The assessment of the disease knowledge and attitude would be done using validated semi-structured questionnaires earlier designed by the principal investigator and used among ambulatory patients with diabetes and/or hypertension accessing care in tertiary healthcare facilities. The validated International Physical Activity Questionnaire (IPAQ) would be utilized for participants' physical activity assessment.

02

Conditions studied

  • Type 2 Diabetes Mellitus
  • Hypertension

Keywords

  • Diabetes
  • Hypertension
  • Interventional study
  • Health literacy
  • Physical activity
  • Medication adherence
  • Pharmacist
  • Community pharmacy
03

In context

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's planned enrollment of 400 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

University of Ibadan is the lead sponsor of 21 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Minimum of 18 years of age
  • Patients must be diagnosed with diabetes and/or hypertension
  • Patients must be on at least one medication
  • Patients who access one of the selected community pharmacies for prescription refill

Exclusion criteria

Exclusion Criteria:

  • Non-consented patients
  • Patients not based at the study site
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Intervention arm

    All participants would undergo educational intervention by pharmacist.

    Behavioral: Educational intervention

Interventions

  • BehavioralEducational intervention

    Educational materials would be given to all the participants. They would also be followed up by pharmacist.

06

What researchers measure

Primary outcomes

  1. Blood pressure control

    Participants' blood pressure in mmHg measured at baseline, 3- and 6-month postintervention would be compared to find out if there are changes.

    Time frame: 6 months

  2. Blood glucose control of participants

    Fasting blood glucose in mg/dL measured at baseline, 3- and 6-month postintervention. would be compared.

    Time frame: 6 months

  3. Participants' level of disease knowledge and attitude

    The knowledge and attitude scale in the semi-structured questionnaire would be evaluated at baseline, 3- and 6-month postintervention.

    Time frame: 6 months

  4. Participants' body mass index calculated by dividing weight in kilograms by the square of height in meters.

    Participants weight in kilograms and height in meters would be measured at baseline, 3- and 6-month postintervention. Their body mass index would be compared to find out if there are changes.

    Time frame: 6 months

  5. Medication adherence of participants using a 4-item medication adherence scale

    Participants' medication adherence would be evaluated at baseline, 3- and 6-month postintervention using Morisky, Green and Levine 4-item medication adherence scale.

    Time frame: 6 months

07

Study locations

1 site
  • Department of Clinical Pharmacy and Pharmacy Administration, Faculty of Pharmacy, University of Ibadan.
    Ibadan, Oyo 200005, Nigeria
08

References and documents

Publications

  • Adeloye D, Owolabi EO, Ojji DB, Auta A, Dewan MT, Olanrewaju TO, Ogah OS, Omoyele C, Ezeigwe N, Mpazanje RG, Gadanya MA, Agogo E, Alemu W, Adebiyi AO, Harhay MO. Prevalence, awareness, treatment, and control of hypertension in Nigeria in 1995 and 2020: A systematic analysis of current evidence. J Clin Hypertens (Greenwich). 2021 May;23(5):963-977. doi: 10.1111/jch.14220. Epub 2021 Feb 18. PubMed 33600078 ↗
  • Uloko AE, Musa BM, Ramalan MA, Gezawa ID, Puepet FH, Uloko AT, Borodo MM, Sada KB. Prevalence and Risk Factors for Diabetes Mellitus in Nigeria: A Systematic Review and Meta-Analysis. Diabetes Ther. 2018 Jun;9(3):1307-1316. doi: 10.1007/s13300-018-0441-1. Epub 2018 May 14. PubMed 29761289 ↗
  • Milosavljevic A, Aspden T, Harrison J. Community pharmacist-led interventions and their impact on patients' medication adherence and other health outcomes: a systematic review. Int J Pharm Pract. 2018 Oct;26(5):387-397. doi: 10.1111/ijpp.12462. Epub 2018 Jun 21. PubMed 29927005 ↗
  • Rajiah K, Sivarasa S, Maharajan MK. Impact of Pharmacists' Interventions and Patients' Decision on Health Outcomes in Terms of Medication Adherence and Quality Use of Medicines among Patients Attending Community Pharmacies: A Systematic Review. Int J Environ Res Public Health. 2021 Apr 21;18(9):4392. doi: 10.3390/ijerph18094392. PubMed 33918990 ↗

Individual participant data

Plan to share: No — I might not share this based on sensitive nature of data to be collected. However, the group data generated would be shared through publications in peer-reviewed journals for public consumption.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2023; primary completion for Apr 2024, 8 months later.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 8 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2023
First posted
Aug 18, 2023
StartEst.
Aug 28, 2023
Primary completionEst.
Apr 2024
CompletionEst.
Jul 2024
Last update
Aug 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05996601
Lead sponsor
University of Ibadan
Responsible party
Akinniyi Akinbiyi Aje (Experiential Training Coordinator and Sub-Dean Undergraduate (Integrated), University of Ibadan) — Principal investigator
First posted
Aug 18, 2023
Start date
Aug 28, 2023 (estimated)
Primary completion
Apr 2024 (estimated)
Completion
Jul 2024 (estimated)
Last update
Aug 18, 2023

Study contacts

Akinniyi A Aje / Dr., PhD
Contact
aje123@gmail.com
+2348035684484 ext. +234
Modupe O Aroyewun / Pharm, B. Pharm
Contact
dupsydaniel@gmail.com
+2348061572544 ext. +234
Aduke E Ipingbemi, PhD
study director · University of Ibadan, Nigeria.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion